SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

CHRS

Coherus Oncology, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor upcoming mid-2026 clinical readouts for tagmokitug and casdozokitug, which could serve as major catalysts. The improved financial position reduces near-term dilution risk, while LOQTORZI's growth trajectory supports potential revaluation if sales continue accelerating.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.95
T+0 close · Mar 9, 2026 · via day close
Latest settled
−24.62%
T+60 · $1.47
Vs SPY
−36.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $1.95entry
  2. T+1 · 8mo ago −8.72%α −8.61% · $1.78
  3. T+5 · 8mo ago −13.85%α −12.94% · $1.68
  4. T+20 · 7mo ago −12.82%α −12.67% · $1.70
  5. T+60 · 6mo ago −24.62%α −36.30% · $1.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up 60% YoY, driven by increasing patient demand and treatment duration. The company significantly reduced its debt by 90% to $38.8 million and bolstered its cash position to $172.1 million through equity financings, while advancing a promising oncology pipeline with multiple 2026 clinical readouts expected.

Key Financial Metrics

Revenue
$42.2M
+59.8% YoY
Adj. EPS
$-1.36
GAAP: $-1.56

Key Facts

  • LOQTORZI net revenue grew 60% YoY to $42.2 million in 2025, up from $26.4 million in 2024
  • Q4 2025 LOQTORZI revenue was $12.4 million, up 64% YoY and 11% QoQ
  • Debt reduced from $480 million peak to $38.8 million by end of 2025
  • Cash, cash equivalents, and marketable securities totaled $172.1 million as of December 31, 2025
  • Company raised $54.9 million in gross proceeds from two equity offerings in late 2025 and early 2026
  • Net loss from continuing operations narrowed to $183.1 million in 2025 from $215.4 million in 2024
  • Phase 2 data for casdozokitug in uHCC showed 38% ORR and 17% CR rate; multiple 2026 clinical readouts expected

Financial Impact

Revenue increased by $15.8 million YoY; net loss improved by $32.3 million; cash position increased by $46.1 million despite operating losses

revenuedebtcashnet lossdilution

Risk Factors

  • High cash burn: $138.5 million used in operating activities in 2025
  • Significant dilution from recent equity raises: ~33 million new shares issued in 2025-2026
  • Pipeline remains early-stage with no guarantees of clinical success

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252311

Track record

15 reports on CHRS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026